Delivery Method: VIA Electronic Mail Reference #: 320-25-43 Product: Drugs Recipient: Recipient Name Mr. Vick Maharaj Recipient Title Chief Executive Officer Marshalls Traditional Healthcare CC 560 […]

On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell […]

For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of […]

Summary Company Announcement Date: February 13, 2025 FDA Publish Date: February 14, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description Bags of POTASSIUM CHLORIDE […]

[2/14/2025] FDA’s Center for Drug Evaluation and Research (CDER) has a qualifying tool to support the development of treatments for alcohol use disorder (AUD). Innovation in treatment […]

Description:  The HL7 Individual Case Safety Report (ICSR) captures information needed to support reporting of adverse events, product problems and consumer complaints associated with the use […]

Image Español Clinical trials help provide reliable evidence needed when studying medical products to diagnose, prevent, treat, and sometimes even cure, childhood diseases. Children who participate […]

Image CaptionAttendees participate in this annual training course where they learn best practices for ensuring data quality and integrity in BSL-4 facilities. Current course | Background […]

Summary Company Announcement Date: July 29, 2023 FDA Publish Date: July 31, 2023 Product Type: Drugs Reason for Announcement: Recall Reason Description Out of Specification Results […]